By Abigail Townsend
Date: Monday 21 Sep 2026
(Sharecast News) - A treatment for a progressive eye disease that is being developed by a Sycona-backed company has delivered positive topline trial results, the life sciences investor confirmed on Monday, sending shares in the FTSE 250 firm sharply higher.
By Iain Gilbert
Date: Monday 22 Jun 2026
(Sharecast News) - Syncona revealed on Monday that non-executive director John Roche had acquired 16,063 ordinary shares in the FTSE 250-listed healthcare investor.
By Josh White
Date: Thursday 18 Jun 2026
(Sharecast News) - Syncona reported broadly stable net asset value for the year ended 31 March on Thursday, as gains at Beacon Therapeutics offset weakness elsewhere in its life sciences portfolio, while the healthcare investor reiterated plans to return at least £250m to shareholders.
| Currency | UK Pounds |
| Price | 117.80p |
| Change Today | 1.80p |
| 52 Week High | 119.00p |
| 52 Week Low | 86.90p |
| Volume | 2,086,237 |
| Shares Issued | 608.20m |
| Market Cap | £716.46m |